SeeThruEquity Issues Update on ChineseInvestors.com, Inc. (CIIX)

SeeThruEquity Issues Update on ChineseInvestors.com, Inc. (CIIX)
SeeThruEquity Issues Update on ChineseInvestors.com, Inc. (CIIX)
by is licensed under

SeeThruEquity has updated its coverage and maintained its price target of $3.75 on shares of ChineseInvestors.com, Inc.’s (OTCQB: CIIX) stock. Among other highlights, the analyst noted the company’s recently released financial results for the full year fiscal 2017. The company reported revenue growth of 75.9% over 2016, with revenues dramatically increasing in both its investor relations and subscription services segments. The analyst also noted the company’s firm focus on the emerging cannabidiol (CBD) health products market. CIIX has high expectations for its wholly owned foreign subsidiary CBD Biotechnology Co. Ltd.’s new “CBD Magic Hemp” skin care line. CBD Biotechnology recently completed the record filing process with the China Food & Drug Administration for its first line of hemp-infused skin care products.

Read the full article

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer


Read More
Tags
Investing, Marijuana Investing
Thumbnail Photo Credit: by is licensed under